Pharming Group N.V.

Yahoo Finance • 10 days ago

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Supplemental New Drug Application (sNDA) resubmission... Full story

Yahoo Finance • 21 days ago

Pharming Group Receives EU Approval For Joenja In Rare Immunodeficiency

(RTTNews) - Pharming Group (PHAR) announced that the European Commission granted marketing authorization for Joenja (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delt... Full story

Yahoo Finance • last month

Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse

Pharma Equity Groups datterselskab Reponex tager vigtigt skridt fremad inden for inflammatorisk tarmsygdom med kommende europæisk patentgodkendelse 11. maj 2026 Meddelelse nr. 7 Pharma Equity Group A/S meddeler i dag, at selskabet... Full story

Yahoo Finance • last month

Pharming Group announces presentations at CIS 2026 Annual Meeting, including leniolisib pediatric data in APDS and clinical experience in CVID and related disorders

Leiden, the Netherlands, May 7, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking plac... Full story

Yahoo Finance • 2 months ago

Pharming Group to report first quarter 2026 financial results and provide business update on May 7

Leiden, the Netherlands, April 23, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and p... Full story

Yahoo Finance • 2 months ago

Pharming Group announces the 2026 Annual General Meeting of Shareholders

Leiden, the Netherlands, April 16, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held o... Full story

Yahoo Finance • 2 months ago

Pharming Group announces the filing of its 2025 Annual Report and Form 20-F

Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. The Annual Report is... Full story

Yahoo Finance • 3 months ago

Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

If approved, Joenja® (leniolisib) would become the first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiencyDecision based on Phase II/III clinical... Full story

Yahoo Finance • 3 months ago

Pharming Group Q4 Earnings Call Highlights

Pharming Group logo Pharming Group (NASDAQ:PHAR) reported what management described as a strong finish to 2025, highlighting double-digit revenue growth, a return to operating profitability, and expanding commercial traction for both RUCO... Full story

Yahoo Finance • 3 months ago

Pharming beats top-line estimates; introduces FY26 outlook

* Pharming press release [https://seekingalpha.com/pr/20434204-pharming-group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong] (PHAR [https://seekingalpha.com/symbol/PHAR]): Q4 GAAP EPS of $0.01 in-line. *... Full story

Yahoo Finance • 3 months ago

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Full year 2025 total revenues increased by 27% to US$376.1 million, driven by continued growth of RUCONEST® and rising demand for Joenja® (leniolisib) Fourth quarter 2025 total revenues increased by 15% to US$106.5 million, compared to the... Full story

Yahoo Finance • 4 months ago

Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and fu... Full story

Yahoo Finance • 4 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR). Such investors are advised to contact Danielle Peyton at newact... Full story

Yahoo Finance • 4 months ago

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day

Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone (KL1333) as the compound... Full story

Yahoo Finance • 6 months ago

Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit

Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, 2025 in New York City.... Full story

Yahoo Finance • 7 months ago

Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow

Total third quarter 2025 revenues increased by 30% to US$97.3 million, compared to third quarter 2024RUCONEST® third quarter revenue increased by 29% to US$82.2 million, compared to third quarter 2024, reflecting sustained growth in patien... Full story

Yahoo Finance • 7 months ago

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London

Leiden, the Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on Novemb... Full story

Yahoo Finance • 8 months ago

Pharming Group to report third quarter 2025 financial results and provide business update on November 6

Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a busine... Full story

Yahoo Finance • 8 months ago

Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio

Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at the American College of Allergy, Asthma &... Full story

Yahoo Finance • 8 months ago

Pharming Group provides update on previously announced G&A expense reduction plan

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company’s growth. The restr... Full story